UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) off The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~February 297, ~~2016~~2017

PROTO SCRIPT PHARMACEUTICAL CORP.

(Exact name of registrant as specified in charter)


Nevada	333-175146	99-0363803
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

9830 6th Street, Suite 103

Rancho Cucamonga, California

91730

(Address of principal executive offices)

(Zip Code)

(855) 476-7679

Registrant’s telephone number

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Item 51.0301

~~Amendments~~Entry tointo ~~Articles~~a ofMaterial ~~Incorporation~~Definitive ~~or Bylaws; Change in Fiscal Year~~Agreement.

~~The~~Item ~~Board of Directors of Proto Script Pharmaceutical Corp~~3. (the “Company”) resolved that in connection with the closing of the Share Exchange, on June 29, 2016, with Proto-Script Pharmaceuticals Corp., a California Corporation (“PCPC”), the Company has changed its fiscal year end to December 31. The Share Exchange is deemed to be a reverse acquisition for accounting purposes, with PSPC, the acquired entity, regarded as the predecessor entity as of June 29, 2016. Starting with the periodic report for the quarter in which the share exchange was completed, the Company will file annual and quarterly reports based on the December 31 fiscal year end of PSPC. Such financial statements will depict the operating results of PSPC, including the acquisition of the Company, from PSPC's inception on June 27, 2001.02

~~SIGNATURES~~Unregistered Sales of Equity Securities.

~~Pursuant~~On toFebruary 7, 2017, Proto Script Pharmaceutical Corp. (the ~~requirements~~“Company”) ofand Michelle Rico (“Rico”), the ~~Securities~~Company’s ~~Exchange~~sole ~~Act~~officer ofand ~~1934~~director, entered into a Share Exchange Agreement (the ~~Registrant~~“Agreement”). Pursuant ~~has~~to ~~duly~~the ~~caused~~Agreement, ~~this~~Rico ~~report~~agreed to beexchange ~~signed~~295,000,000 onshares ~~its~~of ~~behalf~~common bystock that she owns into 1,500,000 shares of Series A Preferred Stock. The Company will cancel the ~~undersigned~~295,000,000 ~~hereunto~~shares ~~duly~~of ~~authorized~~common stock and returned them back to treasury.

	PROTO SCRIPT PHARMACEUTICAL CORP.
Date: November 17, 2016	By:	/s/ Michelle Rico
		Michelle Rico, President

The shares of preferred stock to be issued pursuant to the Agreement, shall be issued in reliance upon an exemption from registration afforded under Section 4(a)(2) of the Securities Act for transactions by an issuer not involving a public offering, or Regulation D promulgated thereunder. The Agreement is an exempt transaction pursuant to Section 4(a)(2) of the Securities Act as the share exchange was a private transaction by the Company and did not involve any public offering.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	PROTO SCRIPT PHARMACEUTICAL CORP.

Date: February 15, 2017	By:	/s/ Michelle Rico
		Michelle Rico, President

Filing Compare · PROTO SCRIPT PHARMACEUTICAL CORP